bullish trajectori upsid spare reiter
overweight rate top pick
baxter host bullish analyst meet monday new york citi second
sinc compani began rebrand hire almeida ceo
cleanli outperform expect last two year manag refresh
target laid target top-lin growth vs
ebita margin vs sustain strong
gener expect vs top
quartil total sharehold return told lead ep
vs street ep rang low-teen
compound-annual-growth-rate assum capit deploy unlik
divers mix end market broad array new product stori set drive
above-market growth across busi baxter look well posit outperform
expect forese futur capit alloc provid opportun
even upsid remain confid manag abil execut
target reiter baxter one top pick
start compani outlook baxter call top-
line growth innov geograph expans
key driver improv outlook growth expect
current portfolio come entir new product penetr
intern market compar end-market collect grow
baxter expect grow faster market busi segment
pharmaceut would grow headwind
gener cyclophosphamid brevibloc total
 continu cost save initi lead
oper margin expans weve alreadi seen roughli save
compani initi zero-bas budget suppli chain optim
manag highlight second wave initi drive continu
margin improv previou guidanc ebita
compar manag expect drive
addit gross margin expans oper expens
improv mix portfolio rebalanc manufactur optim
continu busi transform get
told drive ep ep rang
consensu model forecast rang
provid manag captur street expect low end
importantli guidanc doesnt factor benefit capit deploy
page analyst certif import disclosur
 morgan seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report singl
factor make invest decis
even ignor capit alloc see rang
conserv two main area upsid see margin
expect less upsid compar nonetheless expect initi
target prove conserv compani begin recogn benefit
second wave portfolio optim start manufactur optim
tax guidanc point toward rate signific
step-up saw baxter guid
tax rate busi go continu drive
improv us profit long-rang target factor bare
minimum benefit stock-bas comp could drive rate lower
share continu appreci
deploy cash continu repres singl biggest sourc upsid
long-term estim gener expect reach
baxter set gener
factor compani pay-out ratio target
increment share buyback off-set dilut leav
compani roughli cash acquisit addit share repurchas
assum cash deploy toward share buyback averag share price
alon would add ep coupl
manag willing rais addit capit net debt/ebitda
clear updat target remain conserv base case scenario
turn six product segment medic deliveri expect grow
impli sale
expect come new product key launch includ upcom
launch spectrum iq ou market later year new pump platform
includ lvp syring pump baxter also plan leverag grow
trend favor balanc solut salin clinic data gener
alreadi support use plasma-lyt solut nacl
critic ill patient adjac front piva allow baxter provid
real-tim monitor patient fluid statu next-gener pca
infus pump integr patient monitor reduc advers event
connect pca pump transform innov side new initi
underway creat person therapi patient gener ward
reduc catheter-rel blood stream infect crbsi broad cathet
care mainten portfolio
acut therapi expect grow advanc crrt
take center stage signific percentag baxter growth outlook come
drive increas penetr crrt compani work
gener clinic evid drive peer-to-p educ enabl improv
reimburs anoth sale expect come new product
manag specif highlight upcom launch prismax
geograph expans entir crrt portfolio set
launch japan crrt largest singl opportun acut
therapi baxter also aim doubl organ support revenu
specif focu extracorpor sepsi market opportun grow
look forward manag highlight opportun unlock
market expand continuum care develop new technolog
acut kidney injuri manag
rebuilt product pipelin geograph expans drive above-market
growth histor sleepi advanc surgeri busi context
advanc surgeri pipelin one emptiest
compani flagship tisseal product unchang roughli year manag
aim chang full pipelin product enhanc launch
geograph expans china japan set repres sale
coupl new leadership team restructur global salesforc
us salesforc alreadi replac today manag also
highlight new focu medic educ clinic evid
hcp train alreadi train portfolio
bolster recent acquisit recothrom preveleak baxter first
entranc us basic hemostat segment innov side compani
highlight uniqu opportun leverag salesforc deepen penetr
target surgic specialti use reconstruct microsurgeri platform
renal innov remain key focu compani impress
revenu expect new product key
driver compani above-market growth compound-annual-growth-rate key highlight
includ us launch theranova could repres signific
growth driver includ lrp baxter start
grant differenti reimburs code japanes launch kaguya
system specif featur aim expand home adopt
japanes market today first second gener point
poc offer baxter also aim leverag expertis renal enter
pre-treat prevent space holist take chronic kidney
diseas manag could ultim lead reduc cost
healthcar system better patient outcom
goal nutrit improv therapi adopt address signific
preval malnutrit hospit patient signific portion
baxter revenu expect come new product launch
equal import focu gener new clinic evid support use
parenter nutrit pn use data educ physician
import use pn practic alongsid new product
baxter also see market opportun spread use pn neonat
nutrit oncolog use subcutan administr elderli patient
poor venou access coupl innov improv deliveri formul
pn busi set grow
close main focu baxter busi expand
address market gener inject busi wamgr
broader gener inject market grow baxter expos even
narrow sub-seg grow provid signific opportun
baxter expand presenc market manag highlight goal
almost doubl number molecul new product portfolio
next year address market grow today
lead new product sale growth compound-annual-growth-rate
baxter pois leverag drug deliveri expertis strong hospit channel
presenc develop novel drug deliveri platform also begin manufactur
biosimilar therapeut area oncolog
invest thesi valuat risk
baxter turnaround stori play better expect think there
still plenti room go sinc take januari ceo almeida
transform compani low-margin low-fcf busi one that
significantli under-lev gener signific vs
expand oper margin two year
baxter today top-lin growth busi see upsid potenti
opportun achiev margin expans next five year
driven mix upgrad gross margin improv exist busi
control oper spend that without put work underleverag
balanc sheet debt use drive earn power
either accret larg share buyback neither seem
reflect street model backdrop reiter overweight
rate stock
dec price target valu baxter equal blend
ev/ebitda ep compar large-cap med-tech peer
ev/ebitda ntm assum baxter trade par
peer ev/ebitda appropri given lower leverag level vs
peer premium ep due compani compar top-lin outlook
above-p ep compound-annual-growth-rate upsid potenti capit alloc
risk rate price
downsid risk includ manag inabl deliv margin
expans target misalloc balanc sheet potenti
reimburs price cut
baxter summari financi
cash equival
flow oper activ
o/w chang work capit
flow invest activ
sale
flow financ activ
net chang cash
adj free cash flow firm
compani report morgan estim
note million except per-shar data fiscal year end dec o/w
analyst certif research analyst denot ac cover report certifi multipl research
analyst primarili respons report research analyst denot ac cover within document
individu certifi respect secur issuer research analyst cover research view
express report accur reflect person view subject secur issuer part
research analyst compens directli indirectli relat specif recommend view
express research analyst report korea-bas research analyst list front cover also certifi per
kofia requir analysi made good faith view reflect opinion without undu influenc
